IBI397 or Combination Therapies in Patients With Advanced Malignancies

NCT05245916 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Due to the company's development strategy adjustment

Conditions

Advanced Malignancies

Interventions

DRUG: IBI397
DRUG: IBI397+Sintilimab
DRUG: IBI397+Rituximab

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.